biOasis Technologies, Inc. (TSX VENTURE:BTI) (OCTQX:BIOAF), a biopharmaceutical
company focused on the delivery of therapeutics across the blood-brain barrier
to treat a host of brain diseases and disorders, has been invited to present at
the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the
Palace Hotel in San Francisco. 


biOasis management is scheduled to present at 9:00 a.m. Pacific time, with
one-on-one meetings held throughout the day. Management will discuss the
company's technology, market opportunities and future clinical objectives.  


For additional information or to schedule a one-on-one meeting visit
www.gateway-conference.com and click on the Register/Login tab. You may also
email your request to schedule@gateway-conference.com or call Justin Vaicek at
(949) 574-3860. 


About the Gateway Conference 

The Gateway Conference is designed to provide a unique gateway between
influential members of the investment community and a select group of compelling
publicly-traded companies. Portfolio managers, research analysts and brokers
from buy-side and sell-side institutions will have the opportunity to learn
about more than 50 exciting growth companies across a broad range of industries,
from technology, business and financial services, digital media and clean-tech
to consumer products, retail/e-commerce, life sciences and natural resources.
For more information, visit www.gateway-conference.com. 


The invitation-only conference is hosted by Liolios Group, one of the nation's
top investor relations agencies, and sponsored by leading firms that service the
financial community. For more information about Liolios Group, visit
www.liolios.com. 


ABOUT BIOASIS 

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the Company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca. 


Forward Looking Statements 

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law. 


"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release."


FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778).383.3280
rob@bioasis.ca
www.bioasis.ca


Gateway Conference Contact:
Justin Vaicek
Liolios Group, Inc.
Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di BiOasis Technologies
Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di BiOasis Technologies